Paper Details

  1. Home
  2. Paper Details

Study protocol and rationale for a randomized double-blinded crossover trial of phentermine-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa.

Author: AdlerSarah, DalaiShebani Sethi, NajarianThomas, SaferDebra Lynn

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Qsymia, a medication for obesity, is being investigated as a potential treatment for bulimia nervosa and binge eating disorder. Up to 50% of patients with these disorders remain symptomatic despite treatment, highlighting the need for new therapies. This study protocol focuses on evaluating the safety and efficacy of Qsymia in a Phase I/IIa clinical trial.
Paper Details　
Original Abstract of the Article :
Bulimia nervosa (BN) and binge eating disorder (BED) are associated with severe psychological and medical consequences. Current therapies are limited, leaving up to 50% of patients symptomatic despite treatment, underscoring the need for additional treatment options. Qsymia, an FDA-approved medicati...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.cct.2017.10.007

データ提供：米国国立医学図書館（NLM）

Phentermine-topiramate ER: A Potential Oasis for Binge Eating Disorder and Bulimia Nervosa

Binge eating disorder (BED) and bulimia nervosa (BN), eating disorders characterized by recurrent episodes of binge eating and purging, can have devastating psychological and medical consequences. Current therapies are not always effective, leaving many patients struggling for relief. Qsymia, an FDA-approved medication for obesity, combines phentermine and topiramate ER. This study examines the potential of Qsymia as a new treatment option for BED and BN, offering hope for a more effective and tolerable therapeutic approach.

Exploring new paths in the desert of eating disorders

This study, designed as a Phase I/IIa single-center, prospective, double-blinded, randomized, crossover trial, evaluates the safety and preliminary efficacy of Qsymia for BED and BN. The researchers are investigating whether Qsymia can provide a safe and effective alternative for patients who have not found success with current treatment options. The preliminary findings could pave the way for further research into the potential of this medication for treating these complex eating disorders.

A beacon of hope in the desert of eating disorders

This study offers a potential beacon of hope for individuals struggling with BED and BN. The researchers are carefully examining the safety and efficacy of Qsymia, a promising medication that could provide much-needed relief for those navigating the challenging landscape of eating disorders. It's crucial to continue exploring new treatment options to help individuals find lasting recovery.

Dr. Camel's Conclusion

The desert of eating disorders can be a lonely and daunting place. This study, like a compassionate camel guide, is exploring new paths toward healing. The researchers are working diligently to find safe and effective treatment options, offering a glimmer of hope for those seeking relief from these debilitating disorders.

Date :
  1. Date Completed 2019-02-26
  2. Date Revised 2023-08-27
Further Info :

Pubmed ID

29038069

DOI: Digital Object Identifier

10.1016/j.cct.2017.10.007

Related Literature

Article Analysis
・Effects of phentermine and topiramate
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.